NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its plans to report second quarter 2024 financial results on August 14, 2024, after market close. The company will host a conference call at 4:30 P.M. ET on the same day to discuss the results.
Interested parties can join the call via phone at +1-800-579-2543 (U.S. Toll Free) or +1-785-424-1789 (International). A webcast will also be available. For those unable to attend, a replay will be accessible until August 28, 2024, by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) with the code 11156720. An archived version of the webcast will be available for 90 days.
NEXGEL (NASDAQ: NXGL), un fornitore di prodotti medici e da banco specializzato in idrogeli ultra-delicati ad alto contenuto d'acqua, ha annunciato i suoi piani per riportare i risultati finanziari del secondo trimestre 2024 il 14 agosto 2024, dopo la chiusura del mercato. L'azienda terrà una conferenza telefonica alle 4:30 P.M. ET lo stesso giorno per discutere i risultati.
Le parti interessate possono partecipare alla chiamata telefonicamente al +1-800-579-2543 (numero verde U.S.) o +1-785-424-1789 (internazionale). Sarà disponibile anche un webcast. Per coloro che non possono partecipare, una registrazione sarà accessibile fino al 28 agosto 2024, componendo il +1-844-512-2921 (numero verde U.S.) o +1-412-317-6671 (internazionale) con il codice 11156720. Una versione archiviale del webcast sarà disponibile per 90 giorni.
NEXGEL (NASDAQ: NXGL), un proveedor de productos médicos y OTC especializado en hidrogeles ultra suaves y de alto contenido de agua, ha anunciado sus planes para reportar los resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024, después del cierre del mercado. La empresa realizará una conferencia telefónica a las 4:30 P.M. ET el mismo día para discutir los resultados.
Las partes interesadas pueden unirse a la llamada por teléfono al +1-800-579-2543 (número gratuito de EE. UU.) o +1-785-424-1789 (internacional). También habrá un webcast disponible. Para aquellos que no puedan asistir, una repetición estará accesible hasta el 28 de agosto de 2024, llamando al +1-844-512-2921 (número gratuito de EE. UU.) o +1-412-317-6671 (internacional) con el código 11156720. Una versión archivada del webcast estará disponible durante 90 días.
NEXGEL (NASDAQ: NXGL)는 초부드럽고 고수분 함량의 하이드로겔에 특화된 의료 및 OTC 제품 제공업체로, 2024년 2분기 재무 결과를 2024년 8월 14일, 시장 폐장 후 발표할 계획이라고 발표했습니다. 회사는 같은 날 오후 4:30 ET에 결과를 논의하는 컨퍼런스 콜을 개최할 예정입니다.
관심 있는 분들은 전화로 +1-800-579-2543(미국 무료전화) 또는 +1-785-424-1789(국제전화)로 참여할 수 있습니다. 웹캐스트도 제공됩니다. 참석할 수 없는 분들을 위해, 2024년 8월 28일까지 +1-844-512-2921(미국 무료전화) 또는 +1-412-317-6671(국제전화)로 11156720 코드를 입력하면 재생이 가능합니다. 웹캐스트의 아카이브 버전은 90일간 이용할 수 있습니다.
NEXGEL (NASDAQ: NXGL), un fournisseur de produits médicaux et OTC spécialisé dans les hydrogels ultra-doux à forte teneur en eau, a annoncé ses projets de publication des résultats financiers du deuxième trimestre 2024 le 14 août 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique à 16h30 ET le même jour pour discuter des résultats.
Les parties intéressées peuvent rejoindre l'appel par téléphone au +1-800-579-2543 (numéro gratuit aux États-Unis) ou +1-785-424-1789 (international). Un webcast sera également disponible. Pour ceux qui ne peuvent pas assister, un enregistrement sera accessible jusqu'au 28 août 2024 en composant le +1-844-512-2921 (numéro gratuit aux États-Unis) ou +1-412-317-6671 (international) avec le code 11156720. Une version archivée du webcast sera disponible pendant 90 jours.
NEXGEL (NASDAQ: NXGL), ein Anbieter von medizinischen und OTC-Produkten, der sich auf ultra-sanfte, wasserreiche Hydrogele spezialisiert hat, hat seine Pläne bekannt gegeben, die Finanzergebnisse des zweiten Quartals 2024 am 14. August 2024 nach Marktschluss zu veröffentlichen. Das Unternehmen wird am gleichen Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Interessierte Parteien können telefonisch unter +1-800-579-2543 (US-gebührenfrei) oder +1-785-424-1789 (international) an der Konferenz teilnehmen. Ein Webcast wird ebenfalls zur Verfügung stehen. Für diejenigen, die nicht teilnehmen können, wird eine Wiederholung bis zum 28. August 2024 zugänglich sein, indem sie +1-844-512-2921 (US-gebührenfrei) oder +1-412-317-6671 (international) mit dem Code 11156720 anrufen. Eine archivierte Version des Webcasts wird 90 Tage lang verfügbar sein.
- None.
- None.
Management will host a conference call at 4:30 P.M. ET on the same day
LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2024, after the market closes on August 14, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.
Second Quarter 2024 Financial Results Conference Call
Date: August 14, 2024
Time: 4:30 P.M. ET
Live Call: + 1-800-579-2543 (U.S. Toll Free) or + 1-785-424-1789 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through August 28, 2024 by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11156720. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Valter@KCSA.com
FAQ
When will NEXGEL (NXGL) report its Q2 2024 financial results?
What time is NEXGEL's Q2 2024 earnings conference call scheduled for?
How can investors access NEXGEL's Q2 2024 earnings call?
Until what date will the replay of NEXGEL's Q2 2024 earnings call be available?
